Ginkgo Bioworks Holdings PE Ratio 2020-2022 | DNA

Current and historical p/e ratio for Ginkgo Bioworks Holdings (DNA) from 2020 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Ginkgo Bioworks Holdings PE ratio as of March 21, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Ginkgo Bioworks Holdings PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-03-22 1.22 0.00
2022-12-31 1.69 $-1.19 0.00
2022-09-30 3.12 $-2.29 0.00
2022-06-30 2.38 $-1.96 0.00
2022-03-31 4.03 $-1.55 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.570B $0.478B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.298B 9.44
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.439B 19.34
Arcus Biosciences (RCUS) United States $1.208B 0.00
Biohaven (BHVN) United States $0.950B 0.00
Emergent Biosolutions (EBS) United States $0.405B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.161B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00
Gelesis Holdings (GLS) United States $0.015B 0.00